Pentoxifylline affects cytokine reaction in cardiopulmonary bypass.

Iskesen I., Saribulbul O., Cerrahoglu M., ONUR E., Destan B., Sirin B. H.

The heart surgery forum, vol.9, no.6, 2006 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 9 Issue: 6
  • Publication Date: 2006
  • Doi Number: 10.1532/hsf98.20061090
  • Journal Name: The heart surgery forum
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Manisa Celal Bayar University Affiliated: Yes

Abstract

BACKGROUND: Cardiac surgery is associated with an inflammatory response that may cause myocardial dysfunction after cardiopulmonary bypass. We examined the efficacy of pentoxifylline to attenuate the cardiopulmonary bypass-induced inflammatory response during heart operations. METHODS: In a prospective, randomized study, 30 patients undergoing coronary artery bypass graft surgery received either pentoxifylline (group P, n = 15) (continuous infusion of 1.5 mg/kg per hour during operation) or not (group C [control], n = 15). Blood samples for measurements of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8, and IL-10 were taken from the arterial line in both groups at 5 different time points. RESULTS: TNF-alpha, IL-6, and IL-8 plasma levels increased in both groups after cardiopulmonary bypass, with a higher increase in the control group (P < .05). CONCLUSIONS: Our results indicate that pentoxifylline infusion during cardiac surgery inhibits the proinflammatory cytokine release caused by cardiopulmonary bypass.